Effect of prostavasin in patients with limb ischemia

Evaluation of the Therapeutic Role of Prostavasin in Patients with Critical Limb Ischemia

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT201207292220N4

Enrollment

Registered

2012-08-26

Start date

2008-09-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

critical limb ischemia. Atherosclerosis of arteries of extremities

Interventions

standard protocol of intravenous administration for 21 days. 40 mcg of prostavasin daily in 200 ml of physiological saline solution and infusing the resulting solution i.v. over a period of 2 hours..

Treatment - Drugs

standard protocol of intravenous administration for 21 days. 40 mcg of prostavasin daily in 200 ml of physiological saline solution and infusing the resulting solution i.v. over a period of 2 hours.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria: All patients with rest pain;limb ulcer;gangrene related to arterial occlusive disease who can not tolerat surgery ;and vascular anatomy were unsuitable for reconstruction.enrolled in the study. Exclusion criteria: patients rest pain;limb ulcer;gangrene related to arterial occlusive disease who have tolerated the surgery; and vascular anatomy were suitable for reconstruction, were excluded in the study.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Ankle-brachial index. Timepoint: at presentation, 2 weeks, one month, and three months after the administration. Method of measurement: color doppler sonograghy.;Rest pain. Timepoint: 2 weeks, one month, and three months after the administration. Method of measurement: history and physical examination.;Healing of ulcer. Timepoint: 2 weeks, one month, and three months after the administration. Method of measurement: history and physical examination.;Gangrene. Timepoint: 2 weeks, one month, and three months after the administration. Method of measurement: history and physical examination.	—

Measure

Time frame

Ankle-brachial index. Timepoint: at presentation, 2 weeks, one month, and three months after the administration. Method of measurement: color doppler sonograghy.;Rest pain. Timepoint: 2 weeks, one month, and three months after the administration. Method of measurement: history and physical examination.;Healing of ulcer. Timepoint: 2 weeks, one month, and three months after the administration. Method of measurement: history and physical examination.;Gangrene. Timepoint: 2 weeks, one month, and three months after the administration. Method of measurement: history and physical examination.

—

Secondary

Measure	Time frame
Need to amputation. Timepoint: 2 weeks, one month, and three months after the administration. Method of measurement: history and physical examination.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDerakhshan Far Amir

Shahid Beheshti University of Medical Sciences

amirderakhshanfar@gmail.com+98 21 2272 1144

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026